Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Sales of Ethical Drugs Up 6.2% Driven by Flu-Related Products: Crecon
November 30, 2009
- IMS Health to Be Acquired by TPG and CPP Investment Board
November 30, 2009
- TAK-438 Enters PII for Reflux Esophagitis: Takeda
November 30, 2009
- Kissei: Sales Driven by Urief
November 23, 2009
- NHI Price Listing for 394 Generic Products Announced
November 23, 2009
- Nexavar Enters PIII for Non-Responsive Thyroid Cancer: Bayer, Onyx
November 23, 2009
- Nippon Shinyaku: Sales Down 5.9%
November 23, 2009
- Strong Growth in Sales, Profits Reported by Top-4 Generic Makers
November 23, 2009
- Kyorin: Sales Up 13.5% Driven by Kipres
November 23, 2009
- Zeria: Sales Up Driven by OTC Drugs
November 23, 2009
- Half-year Business Results for Leading Generic Makers
November 23, 2009
- Fuso: Operating Profits Down 56.6%
November 23, 2009
- Univ. Hospitals Should Use More Generics: Mr Isobe
November 23, 2009
- Seikagaku: Sales Up 4.6% Driven by Mainstay Products
November 23, 2009
- GRU WG Reviews Gov't Projects for Saving
November 23, 2009
- Tsumura: Record-High Profits Due to Good Sales of Kampo Medicines
November 23, 2009
- Re-price Long-Listed Drugs Looking at Prices of Generics: WG
November 23, 2009
- Meiji Seika: Pharma Business Up 3.2% Driven by Generics
November 23, 2009
- No Conclusion on 2% Price Adjustment Range
November 23, 2009
- Astellas Licenses Linaclotide from Ironwood
November 23, 2009
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…